BRAF p.V600E mutations are detected in greater than 50% of pediatric Langerhans cell histiocytosis (LCH) lesions. However, the use of mutation-specific BRAF V600E immunohistochemistry (IHC) as a surrogate for molecular testing in pediatric LCH is unknown. We tested the mutation-specific BRAF V600E monoclonal antibody (clone VE1) in formalin-fixed, paraffinembedded LCH samples from 26 pediatric patients (14 males and 12 females, ages 7 mo-17 y) using allele-specific real-time polymerase chain reaction (PCR) with a limit of detection of 0.5% as the comparative gold standard. BRAF VE1 staining was scored for both intensity (0-3+) and percentage of immunoreactive tumor cells (0%-100%). BRAF VE1 immunoreactivity was determined using both lenient (≥1+, ≥1%) and stringent (≥2+, ≥10%) scoring criteria. Using lenient-scoring criteria, we found that the sensitivity and specificity of IHC compared with allele-specific real-time PCR were 100.0% and 18.2%, respectively. The poor specificity of lenient IHC analysis was attributable to weak, 1+ staining in both BRAF-mutated and wild-type LCH.
| INTRODUCTION
Langerhans cell histiocytosis (LCH) is a proliferative disorder that arises from the myeloid dendritic cell precursors.
1,2 Langerhans cell histiocytosis commonly presents in childhood and has a highly variable clinical presentation ranging from isolated skin or bone lesions that typically follow an indolent course, to potentially lethal-disseminated lesions in the bone marrow, the liver, or the spleen. [3] [4] [5] Histologically, LCH lesions are characterized by an aberrant proliferation of neoplastic histiocytes with large reniform and grooved nuclei and a mixed inflammatory infiltrate with abundant eosinophils and occasional multinucleated giant cells. The neoplastic Langerhans cell histiocytes typically express CD1a and CD207 (Langerin), and this characteristic immunophenotype helps distinguish LCH from other histiocyte-rich lesions. 2, 6 The BRAF p.V600E mutation is detected in greater than 50% of pediatric LCH cases, [7] [8] [9] and other V600 codon mutations such as p.V600K, p.V600D, or p.V600R are typically absent. 10 Recurrent MAP2K1 alterations have also been reported in approximately onethird of BRAF wild-type LCH cases highlighting the importance of extracellular signal-regulated kinase (ERK) activation in this neoplastic disease. [11] [12] [13] In children, BRAF p.V600E mutations have been associated with an increased risk of recurrence 9, 14 and high-risk LCH in 1 series. 14 Thus, BRAF mutation analysis of the blood and bone marrow samples is an effective modality to monitor disease and can assist with oncologic therapeutic decision making. 5, 9 BRAF V600E-specific immunohistochemistry (IHC) using a monoclonal antibody specific to the mutated V600E epitope (clone VE1) has been applied to formalin-fixed, paraffin-embedded (FFPE) tissue sections from multiple BRAF p.V600E-positive tumor types. 15 However, the requisite sensitivity and specificity of BRAF VE1 when compared with gold-standard DNA-diagnostic methods are often lacking, and the performance varies considerably among tumor types. [16] [17] [18] [19] [20] [21] The variability of BRAF VE1 sensitivity and specificity is partly attributable to tissue and tumor heterogeneity, nonstandardized scoring criteria, and the chosen comparative molecular method. Mutant BRAF amplification, detection, and interpretation were performed using established laboratory protocols. 35 Briefly, a control, nonpolymorphic region of BRAF exon 3 was amplified in separate wells to ensure DNA integrity and normalize the BRAF p.V600E results. Tissue sample ΔCt values were calculated as the difference between the Ct (crossing threshold) of the p.V600E mutation reaction and the exon 3 control reaction. Samples were determined to be BRAF p.V600E mutation positive if the ΔCt was less than 10, where a ΔCt of greater of equal to 10 was interpreted as negative for the p.V600E mutation.
The lower limit of detection was established as 0.5% (eg, 1 BRAF homozygous mutant cell in approximately 200 BRAF wild-type cells)
per cell-mixing studies.
| BRAF V600E (VE1) immunohistochemistry
Immunohistochemistry was performed using the BOND-III automated Slides were evaluated and scored for VE1-staining intensity (0-3+) and percentage of tumor cells positive for VE1 staining (0%-100% scored in 5% increments) to produce a composite score. BRAF VE1 immunoreactivity was determined by both lenient (≥1+, ≥1%) and stringent (≥2+, ≥10%) scoring criteria as described. 24 VE1-staining intensity was determined as follows: 0+, absence of staining; 1+, faint staining appreciable only at 400× magnification; 2+, moderate staining apparent at 100× magnification with minimal variability in intensity;
and 3+, strong staining apparent at 40× magnification ( Figure 1 ). Three board-certified pathologists blinded to molecular status interpreted and scored VE1 IHC (LYB, KEF, and MJH), and consensus scoring was achieved for all cases by concomitant review.
| RESULTS
Twenty-six pediatric LCH samples (14 males and 12 females; 7 mo-17 y) with corresponding BRAF p.V600E AS-qPCR results (15
Semiquantitative IHC-scoring assessment for BRAF VE1 in pediatric LCH. A semiquantitative IHC-scoring scale (0-3+) was combined with percent staining of neoplastic cell cells (0%-100%) to deduce a composite score (see Methods for additional details). Lenient-scoring criteria considered any cytoplasmic staining of 1+ or greater intensity in any amount of neoplastic tissue (≥1%) as positive. Stringent-scoring criteria required greater than or equal to 2+ staining intensity in greater than or equal to 10% neoplastic cells to be considered positive. Light microscopic images acquired at 400× magnification to highlight 1+ VE1 staining. H&E, hematoxylin and eosin, IHC, immunohistochemistry molecular-positive and 11 molecular-negative) were included in the study. The pertinent characteristics of each patient sample are summarized in Table 1 . Samples were obtained from bone (n = 11), soft tissue (n = 6), lymph nodes (n = 5), skin (n = 2), the liver (n = 1), and the spleen (n = 1). Fourteen patients had multisystem LCH, and 12 patients had single system LCH. Clinical data were limited to the clinical information provided on pathology test requisitions that precluded additional clinical characterization.
Seven bone specimens were subjected to decalcification prior to sectioning. Two decalcified FFPE tissue samples failed AS-qPCR initially, so corresponding nondecalcified sections from the same specimen were tested to determine molecular BRAF positivity (Table 1, denoted by *). Hematoxylin and eosin slides and immunohistochemical stains for CD207 and CD1a were reviewed concurrently to confirm both the diagnosis of LCH and amount of lesional tissue available for scoring. The estimated amount of neoplastic LCH contained in each FFPE section ranged from less than 5% to 95% by H&E light microscopic examination.
The original report, 18 a recent white paper, 36 and the manufacturer's package insert recommend that cytoplasmic staining of 1+ or greater intensity in tumor cells with the VE1 monoclonal antibody be interpreted as positive although no consensus requirement for percent of immunoreactive tumor cells is given (referred to hereafter as lenient scoring criteria: ≥1+, ≥1%). Using these criteria, we found that VE1 staining was absent in 2 cases, and the remaining 24 cases exhibited at least weak (1+) staining in greater than or equal to 10% of neoplastic cells (Table 1) . Thus, the sensitivity and specificity of IHC compared with AS-qPCR using lenient-scoring criteria were 100.0% and 18.2%, respectively ( Table 2 ). The poor specificity of lenient IHC analysis was directly attributable to the weak cytoplasmic staining detected in lesional Langerhans cell histiocytes regardless of BRAF mutation status (Figure 2A ).
To control for the lack of specificity secondary to weak staining, we elected to reanalyze the data using previously established stringent criteria (scored as IHC positive if 2+ or 3+ VE1 staining was detected in ≥10% of neoplastic histiocytes). 24 Using these scoring criteria, we found that 12 cases were scored as VE1 positive, and 14 cases were scored as VE1 negative. Stringent-scoring criteria improved specificity (100.0% vs 18.2%) at the expense of sensitivity (80.0% vs 100.0%, Table 2 ). Notably, 3 VE1 false-negative results were observed ( Figure 2B ), and all contained less than 5% neoplastic tissue and/or were decalcified (Tables 1 and 3 ).
Langerhans cell histiocytosis involves the bone in approximately
90% of pediatric cases, 37 and bone specimens may undergo decalcification prior to histological processing. Importantly, decalcification has been shown to affect DNA quality and interferes with nucleic acid-based assays, 38 although some PCR applications can be optimized for decalcified specimens. [39] [40] [41] We reasoned that if decalcified samples might produce inconclusive molecular results, VE1 may have a certain degree of use in such cases. Therefore, we also analyzed the performance of the VE1 antibody in the 7 Cal-Ex II-decalcified LCH samples included in our study (3 molecular-positive and 4 molecular-negative). The results are summarized in Table 3 .
Both cases with complete absence of staining had been decalcified and demonstrated concordance with corresponding negative molecular studies (Table 3) . One VE1-positive case (2+, 60%) was also molecular-positive and concordant. The remaining 4 decalcified cases demonstrated weak, 1+ staining in variable percentages of neoplastic cells with VE1 immunoreactivity (range, 10%-50%), and were scored VE1-negative using stringent criteria. However, 2 decalcified VE1-negative cases harbored BRAF mutations by molecular analysis (2 falsenegatives). Lastly, the 2 decalcified specimens that required repeat molecular testing due to inconclusive initial results demonstrated very weak VE1 staining (absent and 1+, 10%, respectively), but were concordant with negative molecular results seen in nondecalcified sections from the same specimen. 
| BRAF p.V600E mutation detection by AS-qPCR
The reported prevalence of BRAF p.V600E mutations in pediatric LCH varies widely from 21% 42 to 69% 43 with an average prevalence of approximately 50% 44 . We observed BRAF mutations in 57.7% of samples using an AS-qPCR assay capable of detecting BRAF mutations with high sensitivity (0.5%, 1 mutated allele in 200 wild-type alleles).
For comparison, published sensitivities for BRAF mutation detection using Sanger sequencing, pyrosequencing, and next generation sequencing are approximately 10% to 20%, 5%, and 1% to 2%, respectively. 27, 28 Interestingly, the frequency of 57% is identical to the original publication by Badalian-Very et al who used next generation sequencing methods on CD1a + cells purified from FFPE specimens.
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BRAF wild-type inflammatory cells are recruited to the LCH lesional milieu via several proposed cell autonomous and nonautonomous mechanisms. 8, 9 Therefore, unlike other BRAF-positive malignancies such as melanoma, colorectal carcinoma, or papillary thyroid carcinoma, mutated dendritic cells may comprise only a minor fraction of the composite neoplastic lesion and are typically not amenable to microdissection. Using Sanger sequencing, lower BRAF mutation rates (<30%) were detected in several adult and pediatric LCH studies raising the distinct possibility of false-negative results. 34 ,45,46 Therefore, we recommend that LCH BRAF mutation testing be performed with highly sensitive molecular assays to account for the low-mutant allele fractions intrinsic to LCH and limit potential false-negative molecular results. Additional studies are needed to define the optimal method(s) and requisite lower limit of detection for LCH BRAF mutation testing.
| Immunohistochemistry scoring algorithm: lenient vs stringent scoring
Although thorough technical optimization of the BRAF antibody using control tissue occurred prior to the study, it was clear that optimization of the IHC interpretation for LCH was also required; optimized scoring criteria and highly sensitive comparative molecular gold standards are required to reliably assess the sensitivity and specificity of VE1. 24, 25 In 2 previous studies of BRAF VE1 IHC in LCH, Roden et al considered any cytoplasmic staining as positive staining, 33 and
Mehes and colleagues used a semiquantitative (0-2+) intensity scale. 32 In both studies, false-positive VE1 results were observed.
Likewise in our study, weak, nonspecific cytoplasmic staining was observed in 24 of 26 cases and yielded 9 false-positive VE1 results ( Table 2 ). This nonspecific staining and corresponding suboptimal specificity precluded any meaningful comparisons using lenient IHC-scoring criteria (1+, ≥1%).
Using a stringent scoring algorithm devised for melanoma samples that combined staining intensity (0-3+) and percentage staining of tumor cells (0%-100%), we found that unequivocal IHC staining (2+, ≥10%) was 100.0% specific for an underlying BRAF mutation. (Table 3) .
Collectively, these data suggest that scant and decalcified tissue specimens predispose to false-negative IHC results secondary to scoring inaccuracies and compromised VE1-staining intensity, respectively. For these reasons, VE1 offered no definitive advantage over molecular testing in decalcified LCH tissue sections in our study.
We use a formic acid/formalin solution-based chelation (Cal-Ex II) solution for short duration to minimize nucleic acid hydrolysis and acknowledge that the type of decalcification reagent may have influenced the IHC and molecular results presented here. Therefore, a more extensive study is needed to definitely assess the effects of low-neoplastic tissue content and the effects of various decalcification solutions on the performance of VE1 in LCH using a semiquantitative scoring algorithm.
| CONCLUSION
In this study, we assessed the performance of mutation-specific VE1 using optimized stringent-scoring criteria and compared results to a highly sensitive AS-qPCR molecular method in FFPE tissue samples from 26 pediatric LCH patients. Nonspecific, 1+ cytoplasmic staining in both BRAF-mutated and wild-type LCH initially hindered IHC analysis, but stringent-scoring criteria improved specificity to 100.0%.
Stringent-scoring criteria yielded false-negative results in 20% of cases, and false-negative results were enriched in both decalcified samples and samples with scant neoplastic LCH content. We conclude that strong, 2+, staining in greater than or equal to 10% neoplastic histiocytes is indicative of an underlying BRAF p.V600E
mutation, but all negative VE1 results require additional testing to exclude false-positives. Also, caution should be used when interpreting either decalcified specimens or specimens with scant neoplastic tissue content. Importantly, highly sensitive molecular assays capable of detecting low-level mutations remain the gold standard for BRAF mutation analysis in LCH lesion.
